Inner Mongolia Furui Medical Science Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Inner Mongolia Furui Medical Science de 47.1% y 31.9% por año respectivamente. Se prevé que el BPA crezca en un 49.2% al año. Se espera que la rentabilidad financiera sea de 19.3% en 3 años.

Información clave

47.1%

Tasa de crecimiento de los beneficios

49.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	19.3%
Tasa de crecimiento de los ingresos	31.9%
Rentabilidad financiera futura	19.3%
Cobertura de analistas	Low
Última actualización	26 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Subdued Growth No Barrier To Inner Mongolia Furui Medical Science Co., Ltd. (SZSE:300049) With Shares Advancing 35%

Oct 17

Here's Why We Think Inner Mongolia Furui Medical Science (SZSE:300049) Might Deserve Your Attention Today

Sep 02

Inner Mongolia Furui Medical Science Co., Ltd.'s (SZSE:300049) Intrinsic Value Is Potentially 30% Above Its Share Price

Jul 21

With EPS Growth And More, Inner Mongolia Furui Medical Science (SZSE:300049) Makes An Interesting Case

May 24

We Think Inner Mongolia Furui Medical Science (SZSE:300049) Can Manage Its Debt With Ease

Apr 29

Investors Still Waiting For A Pull Back In Inner Mongolia Furui Medical Science Co., Ltd. (SZSE:300049)

Feb 28

Previsiones de crecimiento de beneficios e ingresos

SZSE:300049 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,771	431	N/A	633	3
12/31/2025	2,159	308	N/A	452	4
12/31/2024	1,584	203	N/A	214	4
9/30/2024	1,327	130	31	225	N/A
6/30/2024	1,272	133	85	289	N/A
3/31/2024	1,234	131	90	273	N/A
12/31/2023	1,154	102	116	305	N/A
9/30/2023	1,097	110	99	282	N/A
6/30/2023	1,084	109	148	268	N/A
3/31/2023	1,042	102	109	223	N/A
1/1/2023	1,009	98	99	189	N/A
9/30/2022	1,017	98	120	197	N/A
6/30/2022	960	86	90	174	N/A
3/31/2022	931	92	134	221	N/A
1/1/2022	898	95	143	223	N/A
9/30/2021	848	90	125	220	N/A
6/30/2021	832	89	83	201	N/A
3/31/2021	780	64	60	169	N/A
12/31/2020	808	62	90	200	N/A
9/30/2020	817	50	79	171	N/A
6/30/2020	808	42	144	210	N/A
3/31/2020	862	47	213	278	N/A
12/31/2019	832	43	190	256	N/A
9/30/2019	858	1	176	269	N/A
6/30/2019	865	3	93	178	N/A
3/31/2019	866	32	24	122	N/A
12/31/2018	867	35	-16	78	N/A
9/30/2018	824	71	23	84	N/A
6/30/2018	799	70	N/A	138	N/A
3/31/2018	844	63	N/A	138	N/A
12/31/2017	823	61	N/A	132	N/A
9/30/2017	882	117	N/A	106	N/A
6/30/2017	886	117	N/A	109	N/A
3/31/2017	858	121	N/A	114	N/A
12/31/2016	827	121	N/A	149	N/A
9/30/2016	709	100	N/A	189	N/A
6/30/2016	671	99	N/A	143	N/A
3/31/2016	608	92	N/A	167	N/A
12/31/2015	604	92	N/A	158	N/A
9/30/2015	649	90	N/A	101	N/A
6/30/2015	668	108	N/A	127	N/A
3/31/2015	634	90	N/A	72	N/A
12/31/2014	646	87	N/A	51	N/A
9/30/2014	567	39	N/A	23	N/A
6/30/2014	564	15	N/A	36	N/A
3/31/2014	533	7	N/A	27	N/A
12/31/2013	523	5	N/A	28	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (47.1% al año) de 300049 es superior a la tasa de ahorro (2.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (47.1% al año) de 300049 crezcan más rápidamente que el mercado CN (25.9% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 300049 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (31.9% al año) de 300049 crezcan más rápidamente que los del mercado CN (13.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (31.9% al año) de 300049 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 300049 sea baja dentro de 3 años (19.3%).

Inner Mongolia Furui Medical Science Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 41% to CN¥43.70

Recent updates

Investor sentiment deteriorates as stock falls 25%

Third quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.11 in 3Q 2023)

Subdued Growth No Barrier To Inner Mongolia Furui Medical Science Co., Ltd. (SZSE:300049) With Shares Advancing 35%

Inner Mongolia Furui Medical Science Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 2Q 2023)

Here's Why We Think Inner Mongolia Furui Medical Science (SZSE:300049) Might Deserve Your Attention Today

Inner Mongolia Furui Medical Science Co., Ltd.'s (SZSE:300049) Intrinsic Value Is Potentially 30% Above Its Share Price

Now 21% undervalued

Inner Mongolia Furui Medical Science Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

With EPS Growth And More, Inner Mongolia Furui Medical Science (SZSE:300049) Makes An Interesting Case

Inner Mongolia Furui Medical Science Co., Ltd., Annual General Meeting, May 21, 2024

We Think Inner Mongolia Furui Medical Science (SZSE:300049) Can Manage Its Debt With Ease

First quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.049 in 1Q 2023)

Inner Mongolia Furui Medical Science Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Investors Still Waiting For A Pull Back In Inner Mongolia Furui Medical Science Co., Ltd. (SZSE:300049)

Inner Mongolia Furui Medical Science Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024

Price target increased by 41% to CN¥43.70

Third quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.11 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.091 in 2Q 2022)

Now 20% undervalued after recent price drop

New major risk - Share price stability

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 20%

Inner Mongolia Furui Medical Science Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 13 June 2023

Inner Mongolia Furui Medical Science Co., Ltd. Approves Cash Dividend for 2022

First quarter 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.033 in 1Q 2022)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.061 in 3Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.12 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Now 24% undervalued after recent price drop

Now 22% undervalued

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.061 (vs CN¥0.06 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.018 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.049 (vs CN¥0.041 in 1Q 2020)

New 90-day low: CN¥7.17

New 90-day low: CN¥8.73

New 90-day low: CN¥9.65

Third quarter earnings released

New 90-day low: CN¥9.69

First half earnings released

Inner Mongolia Furui Medical Science Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento